{"organizations": [], "uuid": "daa8d626d6ee0ad325395e6fae9b1f78d23e8e76", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180417.html", "section_title": "Archive News &amp; Video for Tuesday, 17 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-endo-international-receives-paragr/brief-endo-international-receives-paragraph-iv-notification-on-vasostrict-idUSFWN1RU19T", "country": "US", "domain_rank": 408, "title": "BRIEF-Endo International Receives Paragraph IV Notification On Vasostrict", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.012, "site_type": "news", "published": "2018-04-18T04:44:00.000+03:00", "replies_count": 0, "uuid": "daa8d626d6ee0ad325395e6fae9b1f78d23e8e76"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-endo-international-receives-paragr/brief-endo-international-receives-paragraph-iv-notification-on-vasostrict-idUSFWN1RU19T", "ord_in_thread": 0, "title": "BRIEF-Endo International Receives Paragraph IV Notification On Vasostrict", "locations": [], "entities": {"persons": [{"name": "vasostrict", "sentiment": "negative"}, {"name": "endo", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters) - endo international plc", "sentiment": "neutral"}, {"name": "anda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17 (Reuters) - Endo International PLC:\n* ENDO RECEIVES PARAGRAPH IV NOTIFICATION ON VASOSTRICT * ENDO INTERNATIONAL-LETTER CONTAINS CERTIFICATIONS ALLEGING INVALIDITY,NON-INFRINGEMENT FOR 5 PATENTS CO LISTED IN APPROVED DRUG PRODUCTS FOR VASOSTRICT\n* ENDO IS ASSESSING DETAILS OF NOTICE LETTER AND FORMULATING ITS LEGAL STRATEGY\n* ENDO INTERNATIONAL - NOTICE LETTER ADVISING THAT EAGLE PHARMACEUTICALS SUBMITTED ANDA TO FDA SEEKING APPROVAL TO MARKET GENERIC VERSION OF VASOSTRICT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-18T04:44:00.000+03:00", "crawled": "2018-04-18T18:08:31.034+03:00", "highlightTitle": ""}